1. Anti-infection Apoptosis NF-κB Metabolic Enzyme/Protease
  2. Flavivirus TNF Receptor NF-κB Apoptosis Ser/Thr Protease
  3. Nafamostat mesylate

Nafamostat mesylate  (Synonyms: 甲磺酸萘莫司他; FUT-175)

目录号: HY-B0190A 纯度: 99.85%
COA 产品使用指南

Nafamostat mesylate (FUT-175),一种抗凝剂,是一种人工合成的丝氨酸蛋白酶 (serine protease) 抑制剂。 Nafamostat mesylate 具有抗癌和抗病毒作用,Nafamostat mesylate 通过上调肿瘤坏死因子受体 1 (TNFR1) 的表达诱导凋亡 (apoptosis),可用于动脉壁病理性增厚的发生发展。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Nafamostat mesylate Chemical Structure

Nafamostat mesylate Chemical Structure

CAS No. : 82956-11-4

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥355
In-stock
5 mg ¥200
In-stock
10 mg ¥323
In-stock
25 mg ¥615
In-stock
50 mg ¥984
In-stock
100 mg ¥1575
In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Nafamostat mesylate:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Nafamostat mesylate (FUT-175), an anticoagulant, is a synthetic serine protease inhibitor. Nafamostat mesylate has anticancer and antivirus effect. Nafamostat mesylate induce apoptosis by up-regulating the expression of tumor necrosis factor receptor-1 (TNFR1). Nafamostat mesylate can be used in the development of the pathological thickening of the arterial wall[1][2][3][4].

IC50 & Target

I-kappaBalpha

 

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
Caco-2 CC50
> 20 μM
Compound: NAFAMOSTAT
Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
Toxicity against Caco-2 cells determined at 48 hours by intracellular ATP concentration using the CellTiter-Glo Luminescent Cell Viability Assay
10.21203/rs.3.rs-23951/v1
Caco-2 IC50
0.04 μM
Compound: NAFAMOSTAT
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
Determination of IC50 values for inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells after 48 hours by high content imaging
10.21203/rs.3.rs-23951/v1
体外研究
(In Vitro)

Nafamostat mesylate (10-80 μg/mL, 3-48 h) 通过阻断 IκBα 磷酸化抑制 MDAPanc-28 细胞 NF-κB 活性[1]
Nafamostat mesylate (80 μg/mL, 24-48 h) 通过上调肿瘤坏死因子受体 1 (TNFR1) 的表达诱导 MDAPanc-28 细胞凋亡[1]
Nafamostat mesylate (0.1-10 μM, 24 h) 对 Panc-1 细胞的侵袭能力有抑制作用[2]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: MDAPanc-28 cells
Concentration: 80 μg/mL
Incubation Time: 24 h, 48 h
Result: Substantially reduced the cell viability of MDAPanc-28 cells at both 24 hours and 48 hours.

Cell Invasion Assay[2]

Cell Line: Inhibited NF-κB DNA-binding activity and the degradation of IκBα in a dose-dependent manner as well as in a time-dependent manner.
Inhibited NF-κB DNA-binding activity and the degradation of IκBα in a dose-dependent manner as well as in a time-dependent manner.
Panc-1 cells
Concentration: 0.1 μM, 1 μM, 10 μM
Incubation Time: 24 h
Result: Observed significant inhibition in Panc-1-Try clones at concentrations as low as 0.1 mM.

Western Blot Analysis[1]

Cell Line: MDAPanc-28 cells
Concentration: 10 μg/mL, 20 μg/mL ,40 μg/mL, 80 μg/mL
Incubation Time: 3 h, 8 h, 24 h, 48 h
Result: Inhibited NF-κB DNA-binding activity and the degradation of IκBα in a dose-dependent manner as well as in a time-dependent manner.
Inhibited phosphorylation of IκBα in a time-dependent manner.
体内研究
(In Vivo)

Nafamostat mesylate (10 mg/kg,腹腔注射,一天一次,持续 18 天) 对寨卡病毒 (ZIKV) 感染的 A129 小鼠具有良好的抗病毒作用[3]
Nafamostat mesylate (0.5-2.0 mg/mL (溶于生理盐水中),腹腔注射,一天一次,连续 7 天) 对大鼠颈动脉壁球囊损伤后新生内膜形成有抑制作用[4]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: A129 mice[3]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection (i.p.)
Result: Exhibit delayed lethality and improved survival (40%).
Animal Model: Balloon injury of the rat carotid wall [4]
Dosage: 0.5 mg/mL, 1 mg/mL, 2 mg/mL (dissolved in saline)
Administration: Intraperitoneal injection (i.p.)
Result: Showed smaller ratios of the neointima/medial area.
Showed positive but reduced immunoreactivity of the cells in the neointimal.
Clinical Trial
分子量

539.58

Formula

C21H25N5O8S2

CAS 号
性状

固体

颜色

Off-white to light yellow

中文名称

甲磺酸萘莫司他

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)

溶解性数据
细胞实验: 

DMSO 中的溶解度 : 50 mg/mL (92.66 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 33.33 mg/mL (61.77 mM; 超声助溶)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8533 mL 9.2665 mL 18.5329 mL
5 mM 0.3707 mL 1.8533 mL 3.7066 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验:

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.63 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;再向上述体系中加入 50 μL Tween-80,混合均匀;然后再继续加入 450 μL 生理盐水 定容至 1 mL

    生理盐水的配制:将 0.9 g 氯化钠,溶解于 ddH₂O 并定容至 100 mL,可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.63 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL(饱和度未知)的澄清溶液。

    1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中,混合均匀。

    2 g SBE-β-CD(磺丁基醚 β-环糊精)粉末定容于 10 mL 的生理盐水中,完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
该产品水溶性佳,请具体参考实测 水 / PBS / Saline 中的溶解度数据。
您所需的储备液浓度超过该产品的实测溶解度,如有需要,请与 MCE 中国技术支持联系。
纯度 & 产品资料

纯度: 99.85%

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture and light)。-80°C储存时,请在1年内使用, -20°C储存时,请在6个月内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 1.8533 mL 9.2665 mL 18.5329 mL 46.3323 mL
5 mM 0.3707 mL 1.8533 mL 3.7066 mL 9.2665 mL
10 mM 0.1853 mL 0.9266 mL 1.8533 mL 4.6332 mL
15 mM 0.1236 mL 0.6178 mL 1.2355 mL 3.0888 mL
20 mM 0.0927 mL 0.4633 mL 0.9266 mL 2.3166 mL
25 mM 0.0741 mL 0.3707 mL 0.7413 mL 1.8533 mL
30 mM 0.0618 mL 0.3089 mL 0.6178 mL 1.5444 mL
40 mM 0.0463 mL 0.2317 mL 0.4633 mL 1.1583 mL
50 mM 0.0371 mL 0.1853 mL 0.3707 mL 0.9266 mL
60 mM 0.0309 mL 0.1544 mL 0.3089 mL 0.7722 mL
DMSO 80 mM 0.0232 mL 0.1158 mL 0.2317 mL 0.5792 mL

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Nafamostat mesylate
目录号:
HY-B0190A
需求量: